Spectrum Pharmaceuticals, Inc.  

(Public, NASDAQ:SPPI)   Watch this stock  
Find more results for RAYMOND M. ALLEN�
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 6.36 - 10.32
Open     -
Vol / Avg. 0.00/663,626.00
Mkt cap 471.50M
P/E     -
Div/yield     -
EPS -1.30
Shares 65.74M
Beta 1.85
Inst. own 68%
Mar 4, 2015
Q4 2014 Spectrum Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 19, 2014
Spectrum Pharmaceuticals Inc at Jefferies Global Healthcare Conference - London
Nov 6, 2014
Q3 2014 Spectrum Pharmaceuticals Inc Earnings Call - Webcast
Nov 6, 2014
Q3 2014 Spectrum Pharmaceuticals Inc Earnings Release
Sep 26, 2014
Spectrum Pharmaceuticals Inc at BioCentury Publications NewsMakers in the Biotech Industry
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -24.04% -39.87%
Operating margin -8.60% -24.89%
EBITD margin - -5.96%
Return on average assets -9.40% -12.38%
Return on average equity -17.73% -21.80%
Employees 226 -
CDP Score - -


SUITE 240, 11500 S. EASTERN AVE.,
United States - Map
+1-702-8356300 (Phone)
+1-702-2607405 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Spectrum Pharmaceuticals, Inc. (Spectrum) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. In the United States, the Company markets three oncology drugs, FUSILEV, FOLOTYN and ZEVALIN and also markets ZEVALIN outside of the United States, it has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of drug candidates.Apaziquone is studied in two Phase III clinical trials for non-muscle invasive bladder cancer, or NMIBC, and is under strategic collaborations with Nippon Kayaku Co. Ltd.(Nippon Kayaku), and Handok Pharmaceuticals Co. Ltd. (Handok). Belinostat, is being studied in multiple indications including a Phase II registrational trial for relapsed or refractory peripheral T-cell lymphoma (PTCL), under a strategic collaboration with TopoTarget A/S (TopoTarget). On September 5, 2012, it acquired Allos Therapeutics, Inc.

Officers and directors

Rajesh C. Shrotriya M.D. Chairman of the Board, Chief Executive Officer
Age: 70
Bio & Compensation  - Reuters
Joseph Turgeon President, Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Kurt A. Gustafson Chief Financial Officer, Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Brett L. Scott CPA Senior Vice President - Finance
Age: 62
Bio & Compensation  - Reuters
Lee F. Allen M.D. Ph.D. Senior Vice President, Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Gilles R. Gagnon Director
Age: 60
Bio & Compensation  - Reuters
Luigi Lenaz M.D. Director
Age: 73
Bio & Compensation  - Reuters
Raymond Wayne Cohen Independent Director
Age: 55
Bio & Compensation  - Reuters
Stuart M. Krassner Independent Director
Age: 78
Bio & Compensation  - Reuters
Anthony E. Maida III, Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters